博暉創新(300318.SZ):廣東衞倫擬以1.08億元轉讓汕頭市三聯工業區相關土地使用權及地上附着物
格隆匯12月26日丨博暉創新(300318.SZ)公佈,基於公司戰略規劃及經營發展的長期需要,公司控股子公司廣東衞倫生物製藥有限公司(“廣東衞倫”或“轉讓方”)擬與汕頭市億訊投資有限公司(“億訊投資”或“受讓方”)簽署《國有土地使用權轉讓合同》,雙方就出售資產事宜達成一致,廣東衞倫將位於汕頭市三聯工業區珠浦片區A01-01地塊(東側、西側)及該地塊上的建築物及其他附着物(“標的資產”)按現狀轉讓給億訊投資。根據評估公司出具的評估報吿,此次擬出售的國有土地使用權及地上附着物評估總價為10761.18萬元,經交易雙方協商,廣東衞倫擬以每畝51萬元人民幣的價格轉讓給億訊投資,轉讓總金額為10817.763萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.